Claims for Patent: 8,143,212

Summary for Patent: 8,143,212

Title:	Dalbavancin compositions for treatment of bacterial infections
Abstract:	The invention provides methods and compositions for treatment of bacterial infections. The composition may be a combination of factors, which include A.sub.0, A.sub.1, B.sub.1, B.sub.2, C.sub.0, C.sub.1, isoB.sub.0, and MAG, in the presence of low level solvent. Methods of the invention include administration of dalbavancin formulations for treatment of a bacterial infection, in particular a Gram-positive bacterial infection of skin and soft tissue. Dosing regimens include multiple dose administration of dalbavancin, which often remains at therapeutic levels in the bloodstream for at least one week, providing prolonged therapeutic action against a bacterial infection. Dosing regimens for renal patients are also included.
Inventor(s):	Stogniew; Martin (Blue Bell, PA), Colombo; Luigi (Malnate, IT), Ciabatti; Romeo (Novate Milanese, IT)
Assignee:	Vicuron Pharmaceuticals Inc. (Morristown, NJ)
Application Number:	12/476,785
Patent Claims:	1. A method for treating a bacterial infection in a human in need thereof, the method comprising: administering initial and subsequent therapeutically effective doses of dalbavancin in a pharmaceutically acceptable carrier to the patient, wherein each dose is separated by five to ten days and wherein the amount of the initial dose is about 100 mg to about 5000 mg, and wherein the amount of the initial dose is at least about two times the amount of dalbavancin contained in the subsequent dose. 2. The method of claim 1, the method comprising administering a single subsequent dose. 3. The method of claim 2, wherein the subsequent dose is administered about one week after the initial dose without any intervening dose of dalbavancin. 4. The method of claim 1, the method comprising administering multiple subsequent doses. 5. The method of claim 4, wherein said subsequent doses are administered at about one week intervals without any intervening doses of dalbavancin. 6. The method of claim 1, wherein the bacterial infection is a skin and soft tissue infection. 7. The method of claim 1, wherein the amount of the initial dose is about 200 mg to about 1500 mg. 8. The method of claim 1, wherein the amount of the initial dose is about 1000 mg. 9. The method of claim 1, wherein the amount of the initial dose is about 800 mg. 10. The method of claim 1, wherein the amount of the initial dose is about 500 mg. 11. The method of claim 1, wherein the amount of each subsequent dose is about 400 mg to about 1200 mg. 12. The method of claim 1, wherein the amount of each subsequent dose is about 500 mg. 13. The method of claim 1, wherein the amount of each subsequent dose is about 400 mg. 14. The method of claim 1, wherein the amount of each subsequent dose is about 250 mg. 15. The method of claim 1, wherein the amount of each subsequent dose is about 200 mg. 16. The method of claim 1, wherein the amount of the initial dose is about 1000 mg and the amount of each subsequent dose is about 250 mg.